{"id":45102,"date":"2022-06-15T13:01:47","date_gmt":"2022-06-15T11:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/"},"modified":"2022-06-15T13:01:47","modified_gmt":"2022-06-15T11:01:47","slug":"antibe-therapeutics-announces-amendment-to-warrant-terms","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/","title":{"rendered":"Antibe Therapeutics Announces Amendment to Warrant Terms"},"content":{"rendered":"
\n

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company<\/b>“), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the \u201cWarrant Extension<\/b>\u201d) and amending the exercise price (the \u201cAmended Exercise Price<\/b>\u201d) of 3,117,957 common share purchase warrants (\u201cWarrants<\/b>\u201d) of the Company.\n<\/p>\n

<\/a><\/p>\n

\nWarrant Extension and Amendment<\/span><\/b>\n<\/p>\n

\nThe Warrants, pursuant to the Warrant Extension, will expire on December 31, 2023 and, pursuant to the Amended Exercise Price, be exercisable into a common share of the Company at $1.80 per common share, as depicted in the table below:\n<\/p>\n\n\n\n\n
\n

\nIssue Date<\/b>\n<\/p>\n<\/td>\n

\n

\nNumber of Warrants<\/b>\n<\/p>\n<\/td>\n

\n

\nIssued Exercise Price<\/b>\n<\/p>\n<\/td>\n

\n

\nAmended Exercise Price<\/b>\n<\/p>\n<\/td>\n

\n

\nOriginal Expiry Date<\/b>\n<\/p>\n<\/td>\n

\n

\nAmended Expiry Date<\/b>\n<\/p>\n<\/td>\n

\n

\nEffective Date<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nJune 30, 2020\n<\/p>\n<\/td>\n

\n

\n2,373,401\n<\/p>\n<\/td>\n

\n

\n$6.00\n<\/p>\n<\/td>\n

\n

\n$1.80\n<\/p>\n<\/td>\n

\n

\nJune 30, 2022\n<\/p>\n<\/td>\n

\n

\nDecember 31, 2023\n<\/p>\n<\/td>\n

\n

\nJune 30, 2022\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nAugust 13, 2019\n<\/p>\n<\/td>\n

\n

\n744,556\n<\/p>\n<\/td>\n

\n

\n$4.00\n<\/p>\n<\/td>\n

\n

\n$1.80\n<\/p>\n<\/td>\n

\n

\nAugust 13, 2022\n<\/p>\n<\/td>\n

\n

\nDecember 31, 2023\n<\/p>\n<\/td>\n

\n

\nJune 30, 2022\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nNone of the Warrants are held by insiders of the Company.\n<\/p>\n

\nThe Toronto Stock Exchange has provided conditional approval for the Warrant Extension and Amended Exercise Price with an effective date for the amendments of June 30, 2022.\n<\/p>\n

\nAbout Antibe Therapeutics Inc.
\n
<\/b>Antibe is a clinical stage biotechnology company leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies that target inflammation arising from a wide range of medical conditions. The company\u2019s current pipeline includes assets that seek to overcome the gastrointestinal (\u201cGI\u201d) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (\u201cNSAIDs\u201d). Antibe\u2019s lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids and today\u2019s NSAIDs for post-operative pain. Antibe\u2019s second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company\u2019s anticipated next target is inflammatory bowel disease (\u201cIBD\u201d), a condition long in need of safer, more effective therapies. Learn more at antibethera.com<\/a>.\n<\/p>\n

\nForward-Looking Statements
\n
<\/b>This press release contains forward-looking statements identified by words such as \u201cexpects\u201d, \u201cwill\u201d and similar expressions, which reflect the Company\u2019s current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company\u2019s actual events to differ materially from those projected herein. Investors should consult the Company\u2019s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAntibe Therapeutics Inc.<\/b>
Christina Cameron
\n
VP Investor Relations
\n
+1 416-577-1443
\n
christina@antibethera.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company“), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the \u201cWarrant Extension\u201d) and amending the exercise price (the \u201cAmended Exercise Price\u201d) of 3,117,957 common share purchase warrants (\u201cWarrants\u201d) of … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45102","6":"format-standard","7":"category-industry"},"yoast_head":"\nAntibe Therapeutics Announces Amendment to Warrant Terms - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Antibe Therapeutics Announces Amendment to Warrant Terms - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company“), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the \u201cWarrant Extension\u201d) and amending the exercise price (the \u201cAmended Exercise Price\u201d) of 3,117,957 common share purchase warrants (\u201cWarrants\u201d) of ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-15T11:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220615005402\/en\/718346\/21\/ANTIBE-logo-RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Antibe Therapeutics Announces Amendment to Warrant Terms\",\"datePublished\":\"2022-06-15T11:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/\"},\"wordCount\":402,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005402\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/\",\"name\":\"Antibe Therapeutics Announces Amendment to Warrant Terms - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005402\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"datePublished\":\"2022-06-15T11:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005402\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220615005402\\\/en\\\/718346\\\/21\\\/ANTIBE-logo-RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/antibe-therapeutics-announces-amendment-to-warrant-terms\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Antibe Therapeutics Announces Amendment to Warrant Terms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Antibe Therapeutics Announces Amendment to Warrant Terms - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/","og_locale":"en_US","og_type":"article","og_title":"Antibe Therapeutics Announces Amendment to Warrant Terms - Pharma Trend","og_description":"TORONTO–(BUSINESS WIRE)–Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) (the “Company“), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, announces that it is extending the expiry date (the \u201cWarrant Extension\u201d) and amending the exercise price (the \u201cAmended Exercise Price\u201d) of 3,117,957 common share purchase warrants (\u201cWarrants\u201d) of ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-15T11:01:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220615005402\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Antibe Therapeutics Announces Amendment to Warrant Terms","datePublished":"2022-06-15T11:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/"},"wordCount":402,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220615005402\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/","url":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/","name":"Antibe Therapeutics Announces Amendment to Warrant Terms - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220615005402\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","datePublished":"2022-06-15T11:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220615005402\/en\/718346\/21\/ANTIBE-logo-RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220615005402\/en\/718346\/21\/ANTIBE-logo-RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/antibe-therapeutics-announces-amendment-to-warrant-terms\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Antibe Therapeutics Announces Amendment to Warrant Terms"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45102","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45102"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45102\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}